 Christopher Raeburn
Concepts (372)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 16 | 2026 | 345 | 2.300 |
Why?
| | Neuroendocrine Tumors | 2 | 2022 | 112 | 0.820 |
Why?
| | Reoperation | 2 | 2024 | 630 | 0.720 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2024 | 1137 | 0.710 |
Why?
| | Thyroidectomy | 7 | 2024 | 91 | 0.680 |
Why?
| | Thyroid Carcinoma, Anaplastic | 4 | 2022 | 36 | 0.550 |
Why?
| | Pancreatic Neoplasms | 3 | 2022 | 919 | 0.540 |
Why?
| | Myocardial Ischemia | 3 | 2011 | 285 | 0.500 |
Why?
| | Heart | 4 | 2004 | 636 | 0.460 |
Why?
| | Intercellular Adhesion Molecule-1 | 5 | 2011 | 138 | 0.430 |
Why?
| | Lipopolysaccharides | 6 | 2002 | 863 | 0.420 |
Why?
| | Ischemic Preconditioning | 3 | 2004 | 47 | 0.410 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 3 | 2002 | 40 | 0.410 |
Why?
| | Tumor Necrosis Factor-alpha | 8 | 2010 | 1217 | 0.370 |
Why?
| | Diiodothyronines | 1 | 2011 | 2 | 0.350 |
Why?
| | Propionates | 1 | 2011 | 39 | 0.340 |
Why?
| | Neutrophils | 8 | 2011 | 1134 | 0.330 |
Why?
| | Myocarditis | 1 | 2011 | 102 | 0.310 |
Why?
| | Technetium Tc 99m Sestamibi | 3 | 2015 | 13 | 0.310 |
Why?
| | Parathyroid Glands | 3 | 2015 | 11 | 0.310 |
Why?
| | Ischemic Preconditioning, Myocardial | 4 | 2010 | 35 | 0.310 |
Why?
| | Myocardium | 6 | 2011 | 939 | 0.300 |
Why?
| | Delirium | 4 | 2014 | 104 | 0.300 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2021 | 225 | 0.300 |
Why?
| | Medical Oncology | 2 | 2025 | 332 | 0.300 |
Why?
| | Surgical Procedures, Operative | 2 | 2002 | 270 | 0.290 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2016 | 264 | 0.270 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 210 | 0.270 |
Why?
| | Receptors, Tumor Necrosis Factor | 3 | 2003 | 163 | 0.270 |
Why?
| | Adrenocortical Carcinoma | 2 | 2018 | 67 | 0.260 |
Why?
| | Shock, Hemorrhagic | 4 | 2004 | 201 | 0.250 |
Why?
| | Neck Dissection | 2 | 2024 | 17 | 0.240 |
Why?
| | Receptors, Cell Surface | 3 | 2004 | 377 | 0.240 |
Why?
| | Postoperative Complications | 9 | 2023 | 2919 | 0.240 |
Why?
| | Radionuclide Imaging | 3 | 2013 | 112 | 0.230 |
Why?
| | Thyroid Diseases | 1 | 2026 | 43 | 0.230 |
Why?
| | Biomarkers, Tumor | 5 | 2024 | 1313 | 0.230 |
Why?
| | Myocardial Infarction | 2 | 2011 | 1209 | 0.230 |
Why?
| | Antigens, CD | 3 | 2003 | 555 | 0.220 |
Why?
| | Adrenal Gland Neoplasms | 3 | 2021 | 91 | 0.220 |
Why?
| | Recurrent Laryngeal Nerve Injuries | 1 | 2024 | 16 | 0.220 |
Why?
| | Thyroglobulin | 1 | 2024 | 29 | 0.210 |
Why?
| | Hypocalcemia | 2 | 2015 | 38 | 0.210 |
Why?
| | Iodine Radioisotopes | 4 | 2022 | 136 | 0.200 |
Why?
| | Carcinoma, Neuroendocrine | 3 | 2022 | 35 | 0.200 |
Why?
| | Lymph Node Excision | 1 | 2024 | 173 | 0.200 |
Why?
| | Drosophila Proteins | 2 | 2002 | 212 | 0.200 |
Why?
| | Thyroid Nodule | 1 | 2024 | 56 | 0.190 |
Why?
| | Endotoxemia | 2 | 2010 | 87 | 0.190 |
Why?
| | Osteitis Fibrosa Cystica | 1 | 2002 | 1 | 0.190 |
Why?
| | Humans | 50 | 2026 | 144759 | 0.190 |
Why?
| | Thyroxine | 1 | 2023 | 64 | 0.190 |
Why?
| | Hyperparathyroidism | 1 | 2002 | 11 | 0.190 |
Why?
| | Pheochromocytoma | 2 | 2021 | 58 | 0.190 |
Why?
| | Hypothyroidism | 1 | 2023 | 67 | 0.190 |
Why?
| | Membrane Glycoproteins | 2 | 2002 | 496 | 0.190 |
Why?
| | Iodine | 1 | 2022 | 26 | 0.190 |
Why?
| | Thoracic Surgery | 1 | 2004 | 144 | 0.180 |
Why?
| | Neutrophil Infiltration | 1 | 2002 | 104 | 0.180 |
Why?
| | Prognosis | 5 | 2024 | 4282 | 0.180 |
Why?
| | Adenocarcinoma | 2 | 2022 | 928 | 0.180 |
Why?
| | Chemokines | 4 | 2011 | 218 | 0.170 |
Why?
| | Compartment Syndromes | 1 | 2001 | 36 | 0.170 |
Why?
| | Interleukin-18 | 1 | 2002 | 235 | 0.170 |
Why?
| | Abdomen | 1 | 2001 | 141 | 0.160 |
Why?
| | Regeneration | 1 | 2002 | 197 | 0.160 |
Why?
| | Multiple Trauma | 1 | 2001 | 116 | 0.160 |
Why?
| | Adrenalectomy | 1 | 2000 | 71 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 138 | 0.160 |
Why?
| | Tryptophan | 2 | 2014 | 181 | 0.160 |
Why?
| | Paraganglioma | 1 | 2021 | 53 | 0.160 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 175 | 0.160 |
Why?
| | Middle Aged | 19 | 2024 | 35875 | 0.150 |
Why?
| | Abdominal Injuries | 1 | 2000 | 127 | 0.150 |
Why?
| | Genome-Wide Association Study | 1 | 2026 | 1406 | 0.150 |
Why?
| | Aged | 15 | 2024 | 25913 | 0.140 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2019 | 41 | 0.140 |
Why?
| | Male | 29 | 2024 | 72315 | 0.140 |
Why?
| | Animals | 20 | 2021 | 38058 | 0.140 |
Why?
| | Trans-Activators | 1 | 2021 | 405 | 0.140 |
Why?
| | Stress, Physiological | 1 | 2002 | 453 | 0.140 |
Why?
| | Mice, Inbred C57BL | 8 | 2011 | 5992 | 0.140 |
Why?
| | Stem Cells | 1 | 2002 | 626 | 0.140 |
Why?
| | Treatment Outcome | 6 | 2024 | 11679 | 0.140 |
Why?
| | Adrenal Cortex | 1 | 2018 | 33 | 0.140 |
Why?
| | Myocytes, Cardiac | 1 | 2002 | 556 | 0.130 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 253 | 0.130 |
Why?
| | Mice | 15 | 2021 | 18339 | 0.130 |
Why?
| | Pancreatectomy | 1 | 2000 | 285 | 0.130 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 40 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1455 | 0.130 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2018 | 65 | 0.130 |
Why?
| | Carcinoma | 1 | 2018 | 228 | 0.130 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 4 | 2004 | 81 | 0.120 |
Why?
| | Follow-Up Studies | 2 | 2024 | 5408 | 0.120 |
Why?
| | Cytokines | 2 | 2015 | 2061 | 0.120 |
Why?
| | Protein Kinase Inhibitors | 3 | 2021 | 969 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 1953 | 0.120 |
Why?
| | Adrenal Glands | 1 | 2016 | 77 | 0.120 |
Why?
| | Antibodies | 3 | 2002 | 401 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 433 | 0.120 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 103 | 0.110 |
Why?
| | Virus Latency | 1 | 2016 | 90 | 0.110 |
Why?
| | Sepsis | 1 | 2001 | 640 | 0.110 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 154 | 0.110 |
Why?
| | Multimodal Imaging | 1 | 2015 | 124 | 0.110 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2014 | 44 | 0.100 |
Why?
| | Islets of Langerhans | 1 | 2000 | 833 | 0.100 |
Why?
| | Retrospective Studies | 6 | 2024 | 17066 | 0.100 |
Why?
| | Female | 19 | 2024 | 78271 | 0.100 |
Why?
| | DNA, Viral | 1 | 2016 | 358 | 0.100 |
Why?
| | Carotid Artery Injuries | 2 | 2004 | 39 | 0.100 |
Why?
| | Tunica Intima | 2 | 2004 | 79 | 0.100 |
Why?
| | Elective Surgical Procedures | 2 | 2014 | 201 | 0.100 |
Why?
| | Subtraction Technique | 1 | 2013 | 26 | 0.100 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2015 | 389 | 0.100 |
Why?
| | Preoperative Care | 3 | 2024 | 379 | 0.090 |
Why?
| | Chemokine CCL2 | 2 | 2011 | 115 | 0.090 |
Why?
| | Mice, Knockout | 7 | 2004 | 3121 | 0.090 |
Why?
| | Herpesvirus 3, Human | 1 | 2016 | 336 | 0.090 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2015 | 780 | 0.090 |
Why?
| | Apoptosis | 4 | 2021 | 2430 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2016 | 917 | 0.090 |
Why?
| | Adult | 9 | 2024 | 40449 | 0.090 |
Why?
| | Carcinoma, Papillary | 1 | 2012 | 79 | 0.090 |
Why?
| | Sensitivity and Specificity | 4 | 2024 | 1985 | 0.090 |
Why?
| | Radiopharmaceuticals | 1 | 2012 | 194 | 0.090 |
Why?
| | Fluorescent Antibody Technique | 2 | 2002 | 370 | 0.080 |
Why?
| | Vascular Surgical Procedures | 3 | 2004 | 339 | 0.080 |
Why?
| | Cell Line, Tumor | 4 | 2021 | 3540 | 0.080 |
Why?
| | Young Adult | 3 | 2024 | 14105 | 0.080 |
Why?
| | Patient Care Management | 1 | 2011 | 56 | 0.080 |
Why?
| | Cell Proliferation | 4 | 2021 | 2496 | 0.080 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 186 | 0.080 |
Why?
| | Psychomotor Agitation | 1 | 2011 | 70 | 0.080 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2010 | 76 | 0.080 |
Why?
| | Acute Disease | 2 | 2011 | 1030 | 0.080 |
Why?
| | Extracellular Space | 1 | 2010 | 120 | 0.080 |
Why?
| | Calcium | 1 | 2015 | 1183 | 0.070 |
Why?
| | Risk Assessment | 4 | 2024 | 3671 | 0.070 |
Why?
| | Endotoxins | 1 | 2010 | 221 | 0.070 |
Why?
| | Interleukin-6 | 2 | 2011 | 780 | 0.070 |
Why?
| | Intestinal Perforation | 1 | 2008 | 44 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 291 | 0.070 |
Why?
| | Duodenum | 1 | 2008 | 77 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2015 | 1166 | 0.070 |
Why?
| | Clinical Trials as Topic | 3 | 2018 | 1053 | 0.070 |
Why?
| | Pancreatic Ducts | 1 | 2008 | 81 | 0.070 |
Why?
| | Adolescent | 3 | 2024 | 22428 | 0.070 |
Why?
| | Disease Models, Animal | 3 | 2011 | 4557 | 0.070 |
Why?
| | Wounds, Penetrating | 1 | 2008 | 72 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2010 | 379 | 0.070 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2008 | 237 | 0.060 |
Why?
| | Computer Simulation | 1 | 2011 | 1025 | 0.060 |
Why?
| | Mutation | 4 | 2021 | 4089 | 0.060 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2008 | 219 | 0.060 |
Why?
| | Macrophages | 2 | 2011 | 1511 | 0.060 |
Why?
| | Carotid Arteries | 2 | 2004 | 207 | 0.060 |
Why?
| | Software | 1 | 2011 | 690 | 0.060 |
Why?
| | Hyperplasia | 2 | 2004 | 174 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2730 | 0.060 |
Why?
| | Cell Count | 2 | 2002 | 320 | 0.050 |
Why?
| | Biopsy, Fine-Needle | 2 | 2017 | 68 | 0.050 |
Why?
| | Coronary Disease | 2 | 2004 | 383 | 0.050 |
Why?
| | Transplantation | 1 | 2004 | 33 | 0.050 |
Why?
| | Toll-Like Receptors | 2 | 2002 | 194 | 0.050 |
Why?
| | Vasculitis | 1 | 2004 | 69 | 0.050 |
Why?
| | Time Factors | 5 | 2015 | 7173 | 0.050 |
Why?
| | Insulinoma | 1 | 2003 | 28 | 0.050 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2004 | 157 | 0.050 |
Why?
| | Signal Transduction | 3 | 2016 | 5226 | 0.050 |
Why?
| | Computers | 1 | 2023 | 67 | 0.050 |
Why?
| | Parathyroid Neoplasms | 1 | 2002 | 12 | 0.050 |
Why?
| | Parathyroidectomy | 1 | 2002 | 9 | 0.050 |
Why?
| | Collateral Circulation | 1 | 2002 | 19 | 0.050 |
Why?
| | Cell Physiological Phenomena | 1 | 2002 | 19 | 0.050 |
Why?
| | Neoplasm Staging | 2 | 2018 | 1462 | 0.050 |
Why?
| | Thyrotropin | 1 | 2023 | 118 | 0.050 |
Why?
| | Interleukin-11 | 1 | 2002 | 10 | 0.050 |
Why?
| | Interleukin-10 | 1 | 2004 | 309 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2016 | 508 | 0.050 |
Why?
| | Vinblastine | 1 | 2002 | 75 | 0.050 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2002 | 13 | 0.050 |
Why?
| | Neurosurgical Procedures | 1 | 2004 | 202 | 0.050 |
Why?
| | Immunophenotyping | 2 | 2015 | 322 | 0.050 |
Why?
| | Endosonography | 1 | 2003 | 157 | 0.050 |
Why?
| | Receptors, Cytokine | 1 | 2002 | 36 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2015 | 688 | 0.050 |
Why?
| | Mitochondria, Heart | 1 | 2002 | 102 | 0.040 |
Why?
| | Immunohistochemistry | 3 | 2018 | 1716 | 0.040 |
Why?
| | Risk Factors | 5 | 2012 | 10779 | 0.040 |
Why?
| | Vasopressins | 1 | 2002 | 60 | 0.040 |
Why?
| | Lung | 4 | 2002 | 4109 | 0.040 |
Why?
| | Organ Transplantation | 2 | 2001 | 247 | 0.040 |
Why?
| | Hemostatics | 1 | 2002 | 61 | 0.040 |
Why?
| | NF-kappa B | 4 | 2010 | 661 | 0.040 |
Why?
| | Stem Cell Transplantation | 1 | 2002 | 191 | 0.040 |
Why?
| | Oximes | 1 | 2021 | 26 | 0.040 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2002 | 177 | 0.040 |
Why?
| | Pressure | 1 | 2001 | 225 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1047 | 0.040 |
Why?
| | Indazoles | 1 | 2021 | 80 | 0.040 |
Why?
| | Emergencies | 1 | 2001 | 175 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2003 | 416 | 0.040 |
Why?
| | Adenoma | 1 | 2002 | 218 | 0.040 |
Why?
| | Interleukins | 1 | 2002 | 248 | 0.040 |
Why?
| | Internship and Residency | 1 | 2011 | 1257 | 0.040 |
Why?
| | Neovascularization, Physiologic | 1 | 2001 | 194 | 0.040 |
Why?
| | Laparotomy | 1 | 2000 | 112 | 0.040 |
Why?
| | Cardiovascular System | 1 | 2001 | 137 | 0.040 |
Why?
| | Drug Synergism | 1 | 2021 | 357 | 0.040 |
Why?
| | Myocardial Contraction | 1 | 2001 | 298 | 0.040 |
Why?
| | Neovascularization, Pathologic | 1 | 2001 | 286 | 0.040 |
Why?
| | Ultrasonography | 1 | 2024 | 770 | 0.040 |
Why?
| | Toll-Like Receptor 4 | 3 | 2010 | 276 | 0.040 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2002 | 452 | 0.040 |
Why?
| | Imidazoles | 1 | 2021 | 254 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 919 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 682 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 210 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 310 | 0.040 |
Why?
| | Military Medicine | 1 | 2000 | 149 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2018 | 41 | 0.040 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 3 | 2004 | 41 | 0.040 |
Why?
| | Lamin Type B | 1 | 2018 | 6 | 0.040 |
Why?
| | Graft Rejection | 1 | 2002 | 540 | 0.040 |
Why?
| | NIMA-Related Kinases | 1 | 2018 | 9 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2000 | 289 | 0.040 |
Why?
| | Naphthyridines | 1 | 2018 | 20 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2002 | 499 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 2019 | 251 | 0.040 |
Why?
| | Interleukin-1 | 1 | 2002 | 961 | 0.030 |
Why?
| | Piperazines | 1 | 2021 | 381 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2026 | 2145 | 0.030 |
Why?
| | Thyroid Gland | 1 | 2018 | 88 | 0.030 |
Why?
| | Aldosterone | 1 | 2018 | 43 | 0.030 |
Why?
| | Homeostasis | 1 | 2002 | 640 | 0.030 |
Why?
| | Immunoblotting | 1 | 2018 | 300 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2001 | 541 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 928 | 0.030 |
Why?
| | Carcinoma, Medullary | 1 | 2017 | 16 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2002 | 365 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2018 | 341 | 0.030 |
Why?
| | Aged, 80 and over | 4 | 2016 | 8265 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 172 | 0.030 |
Why?
| | Frozen Sections | 1 | 1996 | 24 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2015 | 3604 | 0.030 |
Why?
| | Hemorrhage | 1 | 2001 | 809 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2000 | 1095 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2002 | 846 | 0.030 |
Why?
| | Cricoid Cartilage | 1 | 2015 | 15 | 0.030 |
Why?
| | Laparoscopy | 1 | 2000 | 475 | 0.030 |
Why?
| | Cardiac Surgical Procedures | 1 | 2002 | 609 | 0.030 |
Why?
| | Varicella Zoster Virus Infection | 1 | 2016 | 27 | 0.030 |
Why?
| | Cell Cycle Checkpoints | 1 | 2016 | 99 | 0.030 |
Why?
| | Tracheostomy | 1 | 1997 | 142 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 102 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 881 | 0.030 |
Why?
| | Taxoids | 1 | 2015 | 116 | 0.030 |
Why?
| | Prospective Studies | 3 | 2015 | 7990 | 0.030 |
Why?
| | Carboplatin | 1 | 2015 | 160 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2015 | 29 | 0.030 |
Why?
| | Herpes Simplex | 1 | 2016 | 98 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 623 | 0.030 |
Why?
| | Herpesvirus 1, Human | 1 | 2016 | 84 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2015 | 164 | 0.030 |
Why?
| | Lung Diseases | 1 | 2001 | 787 | 0.030 |
Why?
| | Disease Progression | 1 | 2002 | 2847 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2015 | 223 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 1045 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2002 | 2925 | 0.030 |
Why?
| | Anilides | 1 | 2014 | 84 | 0.030 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2015 | 141 | 0.030 |
Why?
| | Paclitaxel | 1 | 2015 | 255 | 0.030 |
Why?
| | Niacinamide | 1 | 2014 | 86 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 887 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 628 | 0.030 |
Why?
| | Phenylurea Compounds | 1 | 2014 | 112 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 307 | 0.030 |
Why?
| | Radioactive Tracers | 1 | 2013 | 4 | 0.020 |
Why?
| | Melatonin | 1 | 2014 | 163 | 0.020 |
Why?
| | Doxorubicin | 1 | 2015 | 397 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1489 | 0.020 |
Why?
| | Mice, Inbred Strains | 2 | 2004 | 397 | 0.020 |
Why?
| | Incidence | 2 | 2011 | 2879 | 0.020 |
Why?
| | Cell Movement | 3 | 2001 | 965 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1054 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2014 | 267 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 415 | 0.020 |
Why?
| | Postoperative Care | 1 | 2014 | 288 | 0.020 |
Why?
| | Preoperative Period | 1 | 2012 | 149 | 0.020 |
Why?
| | Serotonin | 1 | 2014 | 293 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1135 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 983 | 0.020 |
Why?
| | Inflammation | 1 | 2003 | 2878 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 333 | 0.020 |
Why?
| | Intraoperative Period | 2 | 2003 | 69 | 0.020 |
Why?
| | Efficiency | 1 | 2011 | 103 | 0.020 |
Why?
| | Pyridines | 1 | 2014 | 605 | 0.020 |
Why?
| | Linear Models | 1 | 2012 | 854 | 0.020 |
Why?
| | Heart Function Tests | 1 | 2010 | 59 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2002 | 851 | 0.020 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 285 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2002 | 2168 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 3077 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2014 | 2029 | 0.020 |
Why?
| | Workload | 1 | 2011 | 170 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2012 | 502 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2011 | 233 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1539 | 0.020 |
Why?
| | Safety | 1 | 2011 | 356 | 0.020 |
Why?
| | Rupture | 1 | 2008 | 91 | 0.020 |
Why?
| | Bile Ducts | 1 | 2008 | 67 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 1129 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2011 | 1306 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2014 | 916 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2012 | 1126 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1173 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 323 | 0.020 |
Why?
| | Survival Analysis | 1 | 2011 | 1382 | 0.020 |
Why?
| | Cattle | 1 | 2010 | 1000 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 529 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 2117 | 0.020 |
Why?
| | Patient Readmission | 1 | 2012 | 758 | 0.020 |
Why?
| | Neoplasms | 1 | 2002 | 2875 | 0.020 |
Why?
| | Phenotype | 1 | 2015 | 3162 | 0.020 |
Why?
| | Patient Care Team | 1 | 2011 | 689 | 0.010 |
Why?
| | Growth Substances | 1 | 2004 | 140 | 0.010 |
Why?
| | Survival Rate | 1 | 2008 | 2089 | 0.010 |
Why?
| | Protein Binding | 1 | 2010 | 2273 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 3333 | 0.010 |
Why?
| | DNA | 1 | 2010 | 1463 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2011 | 3409 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 2003 | 84 | 0.010 |
Why?
| | Monokines | 1 | 2002 | 21 | 0.010 |
Why?
| | Chemokine CXCL2 | 1 | 2002 | 41 | 0.010 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2002 | 93 | 0.010 |
Why?
| | Transcription Factor RelA | 1 | 2002 | 85 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2002 | 251 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2001 | 80 | 0.010 |
Why?
| | Peroxidase | 1 | 2002 | 168 | 0.010 |
Why?
| | Endothelial Growth Factors | 1 | 2001 | 64 | 0.010 |
Why?
| | Lymphokines | 1 | 2001 | 130 | 0.010 |
Why?
| | Toll-Like Receptor 2 | 1 | 2002 | 126 | 0.010 |
Why?
| | Interleukin-8 | 1 | 2002 | 271 | 0.010 |
Why?
| | Wounds, Nonpenetrating | 1 | 2004 | 316 | 0.010 |
Why?
| | Permeability | 1 | 2001 | 168 | 0.010 |
Why?
| | Postoperative Period | 1 | 2002 | 354 | 0.010 |
Why?
| | United States | 1 | 2018 | 15966 | 0.010 |
Why?
| | Protein Transport | 1 | 2002 | 441 | 0.010 |
Why?
| | Cell Division | 1 | 2002 | 766 | 0.010 |
Why?
| | Surgery, Plastic | 1 | 2001 | 52 | 0.010 |
Why?
| | Cohort Studies | 1 | 2011 | 5960 | 0.010 |
Why?
| | Trachea | 1 | 2002 | 261 | 0.010 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 383 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2002 | 636 | 0.010 |
Why?
| | Aorta | 1 | 2002 | 429 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2001 | 557 | 0.010 |
Why?
| | Colorado | 1 | 2008 | 4564 | 0.010 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2002 | 340 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2011 | 6048 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2027 | 0.010 |
Why?
| | Escherichia coli | 1 | 2002 | 854 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1996 | 166 | 0.010 |
Why?
| | Gene Expression | 1 | 2001 | 1490 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 219 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 1996 | 183 | 0.010 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 1997 | 192 | 0.010 |
Why?
| | Coronary Artery Disease | 1 | 2001 | 741 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2002 | 4154 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2002 | 2832 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 1996 | 634 | 0.010 |
Why?
|
|
Raeburn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|